Key FDA decisions urologists can expect in the first half of 2025

There are a number of pending FDA approvals that urologists should keep an eye on as we move through the first half of the year. These include new agents in prostate and bladder cancer, as well as a novel therapeutic for uncomplicated urinary tract infections (uUTIs).